We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Roche 454 Life Sciences and SoftGenetics Sign Co-Promotion Agreement

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

454 Life Sciences, a Roche Company, and SoftGenetics have announced that the two firms have entered into a co-promotion agreement designed to provide users of 454 Sequencing Systems the broad range of next-generation sequencing data analysis options provided by SoftGenetics NextGENe® software.

NextGENe® software is a free standing biologist-friendly software multi-package that is fully compatibility with 454 Sequencing data for a wide variety of applications, including targeted amplicon resequencing, exome sequencing, transcriptome sequencing, forensic profiling and more.

The software package provides additional options for users of 454 Sequencing Systems, in addition to the extensive GS Data Analysis Software suite provided with the platforms.

“This agreement permits both 454 and SoftGenetics the opportunity to more fully understand and address the rapidly changing needs of the NGS marketplace,” states SoftGenetics co-founder John Fosnacht.

Fosnacht continued, “SoftGenetics welcomes the opportunity to work closely with our colleagues at 454 Life Sciences to provide our mutual customers with integrated sequencing and analysis systems that not only delivers the required quality and sensitivity, but also the efficiency needed in today’s scientific and economic environments.”

SoftGenetics offers 30-day trials and no cost web-based training on its genetic analysis software packages.